tirzepatide and kidney linked to lower risk for death, adverse CV outcomes vs. GLP-1s SURPASS-4: Tirzepatide slows kidney disease

[DOI] [PubMed] [Google Scholar] 16.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee

Consider regional variability in pricing and regulatory environments

Additionally, they may indirectly benefit HF by modulating systemic inflammation and improving metabolic profiles [35]

Bischoff, J

Examples include levodopa and carbidopa (brand names Sinemet and Stalevo)

Unlike brand-name Ozempic or Wegovy, which face ongoing supply constraints, compounded versions manufactured by licensed 503A pharmacies offer patients an accessible alternative